Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Allergy & Immunology
•
Drug Allergy
•
Primary Care
Do you believe that pretreatment with montelukast or other LTRAs can reduce the risk of urticaria or angioedema with NSAIDS?
Related Questions
For which patients could you consider direct oral amoxicillin challenge as opposed to skin testing for penicillin allergy de-labeling?
Have you been able to safely use other bisphosphonates in patients who developed an allergic reaction (angioedema) to fosamax?
What medications would you have a patient avoid with an IgE mediated reaction to cyclobenzaprine?
How do you manage atopic dermatitis in pediatric patients who has failed dupilumab?
What is your preferred prophylactic agent in idiopathic angioedema?
Do you give additional pneumococcal vaccines after a dose of PCV20 in patients with asplenia?
Should IVIG dosing in patients with autoimmune disease (i.e., dermatomyositis) who become pregnant continue to be based on actual weight at the time of each infusion, or should it be limited to pre-pregnancy weight?
When do you consider extending the dosing interval for patients on biologics with CRSwNP?
Do you routinely take a cancer history from patients being evaluated for atopy?
What treatment approach do you suggests for a patient with nasal polyp disease and asthma who was improved on dupilumab, but over last 2 years has begun to have increased nasal symptoms and rising eosinophil counts?
